Scotland backs Aimovig for migraine after NICE says no

The Scottish Medicines Consortium (SMC) has given its backing to routine use of the calcitonin gene-related peptide (CGRP) inhibitor throughout NHS Scotland for people who have at least four migraine days per month, and for whom at least three prior preventive treatments have failed.